165 related articles for article (PubMed ID: 8044825)
21. Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH; Kontermann RE; Brinkmann U
Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
[TBL] [Abstract][Full Text] [Related]
22. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
[TBL] [Abstract][Full Text] [Related]
23. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells.
Yu YH; Crews JR; Cooper K; Ramakrishnan S; Houston LL; Leslie DS; George SL; Lidor Y; Boyer CM; Ring DB
Cancer Res; 1990 Jun; 50(11):3231-8. PubMed ID: 2334918
[TBL] [Abstract][Full Text] [Related]
24. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
25. Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity.
Somasundaram C; Arch R; Matzku S; Zöller M
Cancer Immunol Immunother; 1996 Jul; 42(6):343-50. PubMed ID: 8830737
[TBL] [Abstract][Full Text] [Related]
26. Use of immunotoxin to inhibit proliferating human corneal endothelium.
Fulcher S; Lui GM; Houston LL; Ramakrishnan S; Burris T; Polansky J; Alvarado J
Invest Ophthalmol Vis Sci; 1988 May; 29(5):755-9. PubMed ID: 3259213
[TBL] [Abstract][Full Text] [Related]
27. The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography.
Sung C; Dedrick RL; Hall WA; Johnson PA; Youle RJ
Cancer Res; 1993 May; 53(9):2092-9. PubMed ID: 8481911
[TBL] [Abstract][Full Text] [Related]
28. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
29. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
Front Immunol; 2021; 12():719116. PubMed ID: 34484225
[TBL] [Abstract][Full Text] [Related]
30. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells.
Xu FJ; Yu YH; Li BY; Moradi M; Elg S; Lane C; Carson L; Ramakrishnan S
Cancer Res; 1991 Aug; 51(15):4012-9. PubMed ID: 1855217
[TBL] [Abstract][Full Text] [Related]
31. Enhanced binding to antigen of monoclonal antibodies modified with a crosslinker.
Ueno H; Masuko T; Wang J; Hashimoto Y
Biochem Biophys Res Commun; 1993 Mar; 191(2):701-8. PubMed ID: 8096384
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.
Castoldi R; Jucknischke U; Pradel LP; Arnold E; Klein C; Scheiblich S; Niederfellner G; Sustmann C
Protein Eng Des Sel; 2012 Oct; 25(10):551-9. PubMed ID: 22936109
[TBL] [Abstract][Full Text] [Related]
34. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
Wels W; Groner B; Hynes NE
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001
[No Abstract] [Full Text] [Related]
35. Properties of bispecific single chain antibodies expressed in Escherichia coli.
Kranz DM; Gruber M; Wilson ER
J Hematother; 1995 Oct; 4(5):403-8. PubMed ID: 8581376
[TBL] [Abstract][Full Text] [Related]
36. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
[TBL] [Abstract][Full Text] [Related]
37. The comparison of the ability of monoclonal antibodies directed to different proteins (human IgG, human myoglobin and HRP) and bispecific antibodies derived thereof to bind antigens immobilized on a surface of a solid phase.
Dmitriev DA; Massino YS; Segal OL; Smirnova MB; Kolyaskina GI; Pavlova EV; Osipov AP; Egorov AM; Dmitriev AD
Clin Chim Acta; 2001 Jul; 309(1):57-71. PubMed ID: 11408007
[TBL] [Abstract][Full Text] [Related]
38. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
[TBL] [Abstract][Full Text] [Related]
39. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
[TBL] [Abstract][Full Text] [Related]
40. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
